Already a Bloomberg.com user?
Sign in with the same account.
Oct. 25 (Bloomberg) -- Eli Lilly & Co., which has spent $135 million since 2003 training seven generic drugmakers to make treatments against drug-resistant tuberculosis, plans to spend $30 million over the next five years helping patients to get access to the pills.
Lilly plans to work on improving availability of treatment for people in China, India, Russia and South Africa, and to train health-care workers from 2012 until 2016, when it will end its commitment, the Indianapolis-based company’s foundation said in a statement today.
There were about 9.4 million cases of tuberculosis globally in 2009, according to the World Health Organization. Of those, almost 4 percent were a form of the disease that isn’t cleared by the two frontline drugs used against it, requiring treatment with costlier medicines. Lilly’s funds will help make second- line medicines available to those who need it, Chief Executive Officer John Lechleiter said in a telephone interview. He traveled to western China in March to observe the Lilly Foundation’s work.
“The impression that that left me with is the scarcity of resources available to health-care providers,” Lechleiter said. “By that I mean simple things like posters and brochures that would make people aware of the disease, how to prevent it, how to seek treatment.”
--Editors: Robert Valpuesta, Tom Lavell.
To contact the reporter on this story: Simeon Bennett in Geneva at email@example.com
To contact the editor responsible for this story: Phil Serafino at firstname.lastname@example.org